Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
The newly setup entity, Emcutix Biopharmaceuticals Limited, plans to significantly expand Emcure’s offerings
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Strengthening focus in Alzheimer's disease and neuroscience pipeline
The share subscription agreements are being executed at a pre-money equity value of US$ 1.65 billion
Aims to achieve CDMO sales of US$ 400 million by 2028
CSPC will receive an upfront payment of $100 million from AstraZeneca
Grant funding from the Bill & Melinda Gates Foundation will support the rapid and efficient design and synthesis of novel small molecules
Subscribe To Our Newsletter & Stay Updated
